Xeljanz (tofacitinib) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023




$ 3495

In Stock

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Xeljanz (tofacitinib, formerly known as tasocitinib) is an oral, small-molecule inhibitor of JAK3 developed by Pfizer. Xeljanz is a first-in-class drug that was approved for the treatment of RA in the US in 2012, and in Japan in 2013. It is also in development for the treatment of psoriasis (as a topical and oral formulation), psoriatic arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, atopic dermatitis, and juvenile idiopathic arthritis in the seven major markets (7MM; US, 5EU, and Japan).


  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xeljanz (tofacitinib) for the top 2 countries from 2013 to 2023.
  • Sales information covered for the US and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Xeljanz (tofacitinib) performance.
  • Obtain sales forecast for Xeljanz (tofacitinib) from 2013-2023 in top 2 countries (the US and Japan).